CHA
CTXR icon

Cooper/Haims Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Cooper/Haims Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-400
Closed -$10K – 80
2020
Q4 		$10K Hold
400
– – 0.01% 68
2020
Q3 		$10K Buy
+400
New +$11.3K 0.01% 59

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return

Cooper/Haims Advisors's CTXR Position: Q1 2021 in Review

Cooper/Haims Advisors sold out of Citius Pharmaceuticals (CTXR) in Q1 2021, closing a stake of 400 shares — an estimated $10K sold.

Cooper/Haims Advisors first reported a position in CTXR in Q3 2020 and held it in 2 quarters. The position peaked at $10K in Q4 2020. 39 funds tracked by Wall St. Rank hold CTXR as of Q1 2021.

  • Cooper/Haims Advisors reported no remaining Citius Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Cooper/Haims Advisors sold 400 Citius Pharmaceuticals shares in Q1 2021, an estimated $10K.
  • Cooper/Haims Advisors first reported a position in Citius Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Cooper/Haims Advisors's Citius Pharmaceuticals position peaked at $10K in Q4 2020.
  • 39 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2021.

Based on Cooper/Haims Advisors's 13F filing for Q1 2021, filed 28 Apr 2021.